Skip to content

Xenon Pharmaceuticals XENE Prepaid ship and debits

Prepaid ship and debits at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$8.31M+3.1%
GoDaddy logo
GoDaddyGDDY
$246.9M+4.6%
Marathon Digital Holdings logo
Marathon Digital HoldingsMARA
$3.03M-78.7%
Ryan Specialty Holdings logo
Ryan Specialty HoldingsRYAN
$29.72M+87.8%
General Purpose Acquisition Corp.
 logo
General Purpose Acquisition Corp. GPAC
$547.17K+108%
Air Products and Chemicals logo
Air Products and ChemicalsAPD
$171.2M-34.6%

Other financials

Income statement

See full
Revenue--100%
Operating income-$112.3M-54.4%
Net income-$102.3M-57.3%
EPS (diluted)-$1.17-41.0%

Balance sheet

See full
Cash & equivalents$545.9M+368%
Total debt$7.5M-13.6%
Total equity$1.3B+90.0%
Total assets$1.4B+86.6%

Cash flow

See full
Operating cash flow-$88.9M-44.2%
CapEx$133.0K+209%
Free cash flow-$89.0M-44.3%

Valuation

See full
Market cap$5.11B+116%
Enterprise value$4.58B+104%

Profitability

See full
Operating margin-4,974.3%
Net margin-4,612.1%
FCF margin-3,732.2%

Returns & leverage

See full
Return on equity-37.5%+8.7pp
Debt / equity0.0×
Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseNoncurrent.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's prepaid ship and debits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xenon Pharmaceuticals's prepaid ship and debits?
Xenon Pharmaceuticals (XENE) reported prepaid ship and debits of $8.31M in Q1 2026.
How has Xenon Pharmaceuticals's prepaid ship and debits changed year-over-year?
Xenon Pharmaceuticals's prepaid ship and debits increased by 3.1% year-over-year, from $8.05M to $8.31M.
What does prepaid ship and debits mean?
This metric represents the non-current portion of payments made in advance for goods or services that will be received or consumed beyond the next twelve months. For a clinical-stage biopharmaceutical company, this typically includes long-term deposits for contract research organizations, manufacturing capacity reservations, or multi-year software and infrastructure licenses. It reflects the company's commitment of capital to secure future operational resources and long-term research capabilities.